Withdrawal from the cell cycle of dierentiating myocytes is regulated by the myogenic basic helix ± loop ± helix (bHLH) protein MyoD and the pocket proteins pRb, p107 and pRb2/p130. Downstream eectors of`pocket' proteins are the components of the E2F family of transcription factors, which regulate the G 1 /S-phase transition. We analysed by EMSA the composition of E2F complexes in cycling, quiescent undierentiated and dierentiated C2C12 skeletal muscle cells. An E2F complex containing mainly E2F4 and pRb2/p130 (E2F-G 0 /G 1 complex) appears when DNA synthesis arrests, replacing the cyclinA/cdk2 containing E2F complex of proliferating myoblasts (E2F-G 1 /S complex). Serum stimulation reinduces DNA synthesis and the re-appearance of E2F-G 1 /S complexes in quiescent myoblasts but not in dierentiated C2C12 myotubes. In dierentiating C2C12 cells, E2F complexes switch and DNA synthesis in response to serum are prevented when MyoD DNA binding activity and the cdks inhibitor MyoD downstream eector p21 are induced. Thus, during myogenic dierentiation, formation of E2F4 and pRb2/p130 containing complexes is an early event, but not enough on its own to prevent the reactivation of DNA synthesis. Using a subclone of C3H10T1/2 mouse ®broblasts stably expressing Estrogen Receptor-MyoD (ER-MyoD) chimerae, we found that estrogen directed MyoD activation prevents the reassociation of cyclinA/cdk2 to the E2F4 containing complex following serum stimulation and this correlates with suppression of E2F activity and the inability of cells to re-enter the cell cycle. Our data indicate that, in dierentiating myocytes, one mechanism through which MyoD induces permanent cell cycle arrest involves p21 upregulation and suppression of the proliferation-associated cdks-containing E2F complexes formation.
Introduction
In vitro skeletal muscle dierentiation consists in mononucleated myoblasts fusion into multinucleated myotubes (phenotypical dierentiation) which express a coordinate set of muscle-speci®c genes (biochemical dierentiation) (Olson and Klein, 1994) . Prerequisite for myogenic dierentiation is the irreversible withdrawal from the cell cycle (Nadal-Ginard, 1978; Stockdale and Holtzer, 1961) . Master regulators of muscle cell commitment and dierentiation are the members of the MyoD family of myogenic basic Helix ± Loop ± Helix (bHLH) proteins (Lassar and Munstemberg, 1994; Olson and Klein, 1994) , the retinoblastoma protein (pRb) (Gu et al., 1993) and its related proteins p107 and pRb2/p130 (Mayol et al., 1993; Schneider et al., 1994; Shin et al., 1995) .
In conditions permissive for dierentiation, pRb binds MyoD via a region overlapping the`pocket' region (Gu et al., 1993) , a conserved domain, also present in the pRb-related proteins p107 and pRb2/ p130 and required for binding with viral transforming proteins and the members of the E2F/DP family (DeCaprio et al., 1988; Whyte et al., 1989; Dyson et al., 1990; LaThangue, 1994; Wolf et al., 1995) . pRb also binds and inactivates the ubiquitously expressed HLH protein Id2 (Iavarone et al., 1994) , which upon high mitogens concentration sequestrates the E proteins and inhibits MyoD binding to the E-box (Benezra et al., 1990) . Like pRb, also p107 interacts with MyoD in a similar fashion, suggesting that redundance might exist to ensure the dierentiation program under appropriate conditions. However, pRb de®cient cells ± where p107 myogenic functions are recruited, undergo phenotypic myogenic dierentiation, although retaining their ability to re-enter into the cell cycle in response to serum stimulation (Schneider et al., 1994) . This suggests that pRb is critical to prevent DNA synthesis in differentiated myotubes in response to mitogens.
pRb's and the other`pocket' proteins role in the permanent exit from the cell cycle and terminal dierentiation is also suggested by the evidence that the products of the viral oncogenes, i.e. polyomavirus large T antigen, adenovirus E1A and SV40 large T antigens are all able to prevent dierentiation of both primary myoblasts and myogenic cell lines (Graessmann et al., 1973; Webster et al., 1988; Braun et al., 1992; Maione et al., 1992 Maione et al., , 1994 Caruso et al., 1993) and to reinduce DNA synthesis in C2C12 myotubes (Endo et al., 1986; Cardoso et al., 1993; Crescenzi et al., 1995) .
pRb and pRb-related proteins bind and negatively regulate the activity of E2F (Chellapan et al., 1991; Hiebert et al., 1992; Weintraub et al., 1992; Cobrinik et al., 1993; Helin et al., 1993a; Zamanian and LaThangue, 1993; Tommasi and Pfeier, 1995) . E2F is a family of heterodimeric transcription factors madeup of E2F-like and DP-like subunits (LaThangue, 1994) . Many genes involved in DNA replication and cell proliferation that are sequentially activated during the cell cycle ± i.e. c-myc, c-myb, cdc2, thymidine kinase (tk), dihydrofolate reductase (DHFR) ± contain E2F binding sites in their regulatory region (LaThangue, 1994; Nevins, 1992) . At least seven genes encoding for components of the E2F family have been cloned (E2F from 1 to 5, DP1 and DP2) (Helin et al., 1992 (Helin et al., , 1993b Kaelin et al., 1992; Shan et al., 1992; IveyHoyle et al., 1993; Beijersbergen et al., 1994; Ginsberg et al., 1994; Li et al., 1994; Hijmans et al., 1995; Zhang and Chellapan, 1995) . Multiple evidences indicate that E2F1 plays a critical role in regulating G 1 /S phase transition (Johnson et al., 1993; Sala et al., 1994; Kowalik et al., 1995) and deregulated expression of E2F1 leads to apoptosis in certain cell types (Shan and Lee, 1994; Qin et al., 1994) . In muscle cells, E2F1 overexpression inhibits myogenic dierentiation . In association with DP1, E2F1 binds underphosphorylated pRb and forms a complex which retains its DNA-binding property but is not able to activate transcription (Weintraub et al., 1992; Helin et al., 1993a) . In many cell types the pRb-E2F complex is a minor component of the G 0 E2F-DNA binding activity (Chittenden et al., 1993; Dou et al., 1994; Schwarz et al., 1993) . In unstimulated human T cells and in growth arrested murine ®broblasts an E2F complex, formed by E2F4 and pRb2/p130, has been detected (Cobrinik et al., 1993; Vairo et al., 1995) . This complex can play a role in inducing and/or maintaining cellular quiescence (Claudio et al., 1994; Vairo et al., 1995) . Functional studies have demonstrated that pRb2/p130 suppress E2F4 but not E2F1 mediated trans-activation and that E2F4 coexpression is able to overcome pRb2/p130 mediated G 1 arrest more eciently than Rb-induced G 1 blockade (Vairo et al., 1995) . E2F4 also forms heterodimers with members of the DP family and p107 (Beijersbergen et al., 1994; Ginsberg et al., 1994) , an association occurring in late G 1 or at the G 1 /S boundary (Schwarz et al., 1993) . In addition, both p107 and pRb2/p130 have been described to associate with cyclin E and A and their dependent kinase cdk2 to form E2F-containing complexes in late G 1 and S-phase, respectively (Devoto et al., 1992; Lees et al., 1992; Pagano et al., 1992; Hannon et al., 1993; Li et al., 1993) . However, the functional consequences of these multimeric interactions have not been fully de®ned.
These observations prompted us to analyse the composition of E2F-associated complexes in C2C12 skeletal muscle cells at critical time points of myogenic dierentiation. Changes in E2F/DP complexes were correlated with cell cycle progression, G 0 entry, irreversible withdrawal from the cell cycle as well as with MyoD DNA binding activity and its downstream target in muscle, the cdks inhibitor p21 (Guo et al., 1995; Halevy et al., 1995) . We found that, as cells enter the quiescent state, an E2F4-pRB2/p130 containing complex appears. The same complex is present in dierentiated myotubes. In absence of MyoD activity and p21 up-regulation, the E2F4-pRb2/p130 complex is unable to induce the permanent withdrawal from the cell cycle, thus suggesting that its appearance only re¯ects growth arrest, and that MyoD/p21 activity is required to prevent re-formation of cyclinA/cdk2 containing E2F complexes and S-phase entry in dierentiated myocytes upon serum stimulation.
Results
E2F complexes in cycling, G 0 /G 1 arrested and dierentiated C2C12 cells C2C12 skeletal muscle cells were used to study the E2F complexes composition in dierent culture conditions. In high serum (20% FCS) C2C12 myoblasts actively proliferate, as demonstrated by high levels of 5-Bromo-2 deoxy-Uridine (BrdU) incorporation ( Figure 1A ). Full dierentiation into mature multinucleated myotubes is obtained by culturing con¯uent C2C12 cells in low serum (2% FCS; DM, dierentiation medium). C2C12 myotubes do not incorporate BrdU ( Figure 1F ) and display several muscle-speci®c markers, such as myosin heavy chain (MHC) ( Figure 1C ). When C2C12 cells are kept in the absence of serum (0.1% FCS) before con¯uence is reached, quiescent undierentiated mononucleated myoblasts can be observed between 24 and 48 h after starvation. These quiescent myoblasts do not incorporate BrdU ( Figure 1E ) and do not express muscle speci®c markers ( Figure 1B) , although retaining the ability to proliferate in response to mitogens (Puri et al., 1995) .
For gel retardation assays, cell extracts were prepared from noncon¯uent C2C12 cells cultured in 20% serum enriched medium (cycling myoblasts), from noncon¯uent C2C12 cells cultured in 0.1% serum (quiescent myoblasts) and from C2C12 dierentiated myotubes. We detected four E2F complexes whose formation is dierentially regulated along the cell cycle and during dierentiation (Figure 2a) . The binding speci®city of each E2F complex was con®rmed by competition experiments with excess unlabelled wild type and mutant E2F speci®c oligonucleotides ( Figure  2b ) and unrelated unlabelled DNA (data not shown). The slower migrating band (E2F-G 1 /S complex), detected in cycling myoblasts, disappears when cells enter G 0 (C2C12 quiescent) being replaced by a faster migrating band (the E2F-G 0 /G 1 complex) also found in dierentiated C2C12 myotubes. Two additional faster migrating bands were observed in all cell cycle phases, but were more evident in cycling myoblasts then in quiescent cells. Fully dierentiated myotubes display faster migrating bands similar in abundance to those detected in quiescent cells. These E2F complexes were named E2F-free 1 and 2, based on the results obtained using deoxycolate (DOC) treatment to dissociate E2Fs from their associated proteins (Figure 2c ). DOC abolished in a dose dependent manner both the E2F-G 1 /S (Figure 2c, lanes 3 and 4) and the E2F-G 0 /G 1 (Figure 2c , lanes 6, 7 and 9 ± 10) complexes, but not the free E2F forms, which simultaneously increased in abundance, indicating the release of free E2F from the multimeric complexes. The ®fth retarded band ( Figure  2a ) is nonspeci®c, being abolished by both wild type and mutant E2F oligonucleotides (Figure 2b ), as well as by unrelated unlabelled DNA (data not shown). During the transition from cycling to quiescent C2C12 myoblasts, a mixed population of G 0 /G 1 arrested cells together with dividing myoblasts can be observed. E2F gel retardation assays, performed with extracts from this mixed-cell population, reveal the coexistence of the E2F-G 0 /G 1 and E2F-G 1 /S bands in addition to the E2F free forms (data not shown). During myogenic dierentiation, cells asyncronously fuse into myo-tubes. This process starts after around 18 h of culture in dierentiation medium (early dierentiation) and lasts for up to 96 h (late dierentiation). At this time the vast majority of cells are dierentiated myotubes and only very few mononucleated satellite MHC negative myoblasts are observed ( Figure 1C and F) . We monitored E2F complexes along the entire time of dierentiation and we found that either in early or in late dierentiation the electrophoretic mobility of E2F-G 0 /G 1 and free E2F detected bands was identical (data not shown).
The composition of the dierent E2F complexes was determined by gel retardation supershifting assays using a panel of speci®c antibodies directed against proteins that have been shown to form complexes with E2Fs. Since in many cell types an E2F complex containing E2F-p107-cyclinA-cdk2 appears around the time of DNA synthesis, we ®rst tested anti-cyclinA and anti-cdk2 antibodies. Polyclonal anti-cdk2 antibody supershifted ( Figure 3a (Figure 3a , lane 4). In addition, an anti-pRb2/p130 monoclonal antibody was found to supershift the G 1 /S complex ( Figure 3b , lane 4), according to the previously reported association between pRb2/p130 and the G 1 / S speci®c cyclins A and E and their associated kinase cdk2 (Cobrinik et al., 1993; Lees et al., 1992) . Using a panel of antibodies against the dierent members of the E2F family, we identi®ed E2F4 as the major component of the E2F-G 1 /S complex(es) (Figure 3b , lane 2). Thus, in C2C12 proliferating cells the G 1 /S speci®c E2F complex(es) contains p107 and/or pRb2/ p130, cyclinA, cdk2 and E2F4. E2F4 and its negative regulator pRb2/p130 (Figure 3d , lanes 2 and 4), but not cyclinA and cdk2 (Figure 3c , lanes 2 and 5), were also part of the faster migrating complex which, during dierentiation, replaces the E2F-G 1 /S band, in coincidence with DNA synthesis arrest (E2F-G 0 /G 1 complex). The failure to completely supershift this band with both anti-E2F4 and anti-pRb/p130 antibodies addition, either alone (Figure 3d ) or in combination (data not shown), would imply for the presence of other(s) component(s) in this complex. This is also suggested by the observation that both SV40 TAg and adenovirus E1A, which are able to disrupt`pocket proteins'-E2F/DP interactions, reduce Plabelled E2F speci®c probe. (c) DOC release of E2F activities. DOC treatment and EMSAs from cycling C2C12 (lanes 2 to 4), quiescent C2C12 (lanes 5 to 7) cells and C2C12 myotubes (lanes 8 to 10) were performed as described in Materials and methods. DOC was used at the concentration of 0.4% (lanes 3, 6 and 9) and 0.8% (lanes 4, 7 and 10) (wt/vol) C2C12 cycling C2C12 quiescent C2C12 myotubes
the abundance of this complex without completely abolishing it (manuscript in preparation). We also observed that E2F4 is the E2F family member predominantly expressed in both cycling and quiescent myoblasts as well as in myotubes, being E2F1 expression restricted to the G 1 /S-phase cells ( Figure  3f ). To verify the presence of pRb in E2F complexes, four dierent anti-pRb antibodies were used, including the anti-pRb XZ ± which is able to aect the MyoDpRb complex present in C2C12 myotubes (Gu et al., 1993) . None caused a clear supershift and/or disruption of either the G 0 -speci®c complex or any of the other E2F complexes detected in cycling ( Figure 3e ) and quiescent myoblasts (data not shown) as well as in early myotubes ( Figure 3e ). Moreover, in agreement with the observation made by Corbeil et al. (1995) , the XZ anti-pRb monoclonal was found to supershift the E2F-G 0 /G 1 band in 5 days old myotubes (data not shown). A minor supershift of the G 0 /G 1 band in early myotubes was also observed with an anti-p107
Figure 3 Antibody shift EMSAs of E2F complexes from C2C12 cycling myoblasts (a and b) and from dierentiated C2C12 myotubes (c and d). In (e): antibody shift EMSA E2F complexes from both C2C12 cycling myoblasts and dierentiated C2C12 myotubes were performed using a panel of antibodies speci®c for pRb. In 8) and after (lane 9) serum stimulation were assayed for E2F EMSA as described in Materials and methods. In lanes 10 and 11 extracts were prepared from dierentiated myotubes before and after 24 h serum stimulation, respectively monoclonal antibody (Figure 3c , lane 3). These results suggest that E2F4 and pRb2/p130 are the major components of the E2F complexes found in both G 0 -arrested C2C12 cells and dierentiated myotubes. p107 and pRb can also be found in E2F-G 0 /G 1 complexes as minor components, with a mutually exclusive kinetics of appearance during the dierentiation.
Irreversible loss of cyclins/cdks association to E2F-DNA binding complexes in dierentiating C2C12 cells
The interaction between E2F4 and pRb2/p130 has been described to regulate negatively E2F activity and to determine the inhibition of cell cycle progression in certain cell types (Claudio et al., 1994; Vairo et al., 1995) . In muscle cells, this interaction has been implicated in the irreversible cell cycle withdrawal (Shin et al., 1995) . Since the E2F-G 0 /G 1 complex appears after only few hours of serum removal, both in con¯uent and noncon¯uent C2C12 cells, well before phenotypical and biochemical dierentiation is observed, we examined the behaviour of this complex in response to serum stimulation in both quiescent and dierentiated C2C12 cells. As shown in Figure 4a , the E2F-G 0 /G 1 complex (lane 2) disappears upon serum stimulation in C2C12 noncon¯uent cells starved for 24 h in 0.1% FCS, and is replaced by a slower E2F complex (lane 3) which comigrates with the E2F-G 1 /S complex speci®c of cycling C2C12 myoblasts (lane 1). C2C12 semicon¯uent cells cultured for 12 h in absence of serum display the same behaviour (lanes 4 and 5). In C2C12 con¯uent cells ± cultured in dierentiation medium for either 18 (early dierentiation) (lanes 6 and 7) or 96 h (late dierentiation) (lanes 8 and 9) ± serum stimulation is unable to aect the E2F-G 0 /G 1 complex. In addition both quiescent and con¯uent C2C12 cells cultured in dierentiation medium, as well as mature myotubes, responded to serum with a detectable increase of the slower migrating band of the E2F free species (lanes from 2 to 9, and 10, 11). The ability to respond to serum stimulation with a switch from the E2F-G 0 /G 1 complex to the E2F-G 1 /S complex temporally correlated with the ability to incorporate BrdU ( Figure 4b ). Cells unresponsive to serum were mostly positive for muscle speci®c markers, such as MHC and exibited strong immunoreactivity for MyoD and p21, when compared to BrdU positive myoblasts (data not shown). Although a very small proportion of satellite unfused myoblasts, surrounding the myotubes, can respond to serum with BrdU incorporation (Figure 4b , lanes 7 and 9), should cyclins/cdks reassociation to the E2F complex occurs in these cells it is undetectable by EMSA.
The role of MyoD in the control of E2F-complexes and the irreversible cell cycle exit
Permanent cell cycle arrest in muscle cells results from a combination of events. Among these, MyoDdependent p21 upregulation has been proposed as a key mechanism to block cdks activity in terminally dierentiated myocytes (Guo et al., 1995; Halevy et al., 1995) . When culture conditions are permissive for dierentiation, MyoD becomes able to bind the DNA at the E-box sites and to promote muscle speci®c genes transcription (Olson and Klein, 1994). To correlate MyoD activity with E2F complexes changes during dierentiation, we determined MyoD DNA binding levels in either cycling or quiescent myoblasts and in myotubes. EMSA experiments using an E-box oligonucleotide ( Figure 5a ) demonstrated that conuent C2C12 cells cultured in dierentiation medium display increasing amounts of E-box DNA binding activity, starting at 18 h (lane 2), and reaching higher levels in mature myotubes (lane 3). The E-box complex detected in myotubes includes two bands with dierent electrophoretic mobility. The slower migrating band appears in early dierentiation and was speci®cally supershifted by an anti-MyoD antiserum but not by the preimmune serum (Figure 5b ). The faster migrating band appears later during the dierentiation and is supershifted by an anti-myogenin antiserum (data not shown). This increase in MyoD DNA binding activity, temporally correlates with p21 levels upregulation (Figure 6 ) and the absence of E2F complexes-switch and BrdU incorporation in response to serum (Figure 4b ). Taken together, our results suggest that the E2F-G 0 /G 1 complex is indeed associated with quiescence, but would not be by itself sucient to maintain permanent withdrawal from the cell cycle. In addition, our data would also imply that MyoD, possibly through its downstream target, the cdks-inhibitor p21, is responsible for preventing reestablishment of the proliferation-associated E2F complex(es).
Since we failed to supershift E2F complexes with an anti-MyoD antiserum or to detect any E-box binding activity when extracts from myotubes were anity puri®ed with biotinilated E2F oligonucleotides (data not shown), MyoD ability to in¯uence E2F complexes composition would not involve a direct physical association at the E2F DNA sites. To further investigate the role of MyoD activity induction in the modulation of E2F DNA binding complexes composition and activity, we used a subclone of C3H10T1/2 mouse ®broblasts stably expressing Estrogen ReceptorMyoD (ER-MyoD) chimerae (Hollemberg et al., 1993) . In these cells, MyoD and myogenesis become hormone inducible. Upon treatment with estradiol ER-MyoD localizes into the nuclei (Hollemberg et al., 1993) and this results in the induction of E-box binding activity (Figure 7a ), p21 and myogenin transcription ( Figure  7b ) and ®nally, in the myogenic conversion of ®broblasts showing high nuclear p21 expression (Figure 7c ). When MyoD is activated by estradiol, cells undergo cell cycle arrest, E2F-driven transcription is suppressed, as expected (Figure 8a ), association of cyclinA/cdk2 with E2F complexes is prevented ( Figure  8b, lane 4) , the E2F4-pRb2/p130 complex becomes refractory to the addition of serum (Figure 8b , lane 5) and cells are unable to re-enter the cell cycle ( Figure  8c ). The link between MyoD/p21 induction and the control of proliferation in muscle cells was further reinforced by the observation that MyoD overexpression in cycling myoblasts, by direct microinjection of a MyoD expression vector, results in both the inhibition of cell proliferation and the increase of p21 nuclear expression ( Figure 9 and Table 1 ).
Discussion
In this study we analysed the composition of E2F complexes along the cell cycle and during myogenic dierentiation of C2C12 mouse skeletal muscle cells. We de®ned two prominent complexes: the ®rst contains E2F4, p107 and/or pRb2/p130 together with cyclinA and cdk2 and is present in cycling myoblasts; the latter appears upon serum withdrawal (G 0 /G 1 phase) and contains E2F4 and pRb2/p130, as the major components. In addition, we demonstrate that, when MyoD DNA binding activity and p21 levels increase, the reassociation of cyclins/cdks with E2F is prevented, the E2F4-pRb2/p130 containing complex become refractory to the addition of serum and the cells are unable to re-enter the cell cycle.
E2F/DP family has been involved in transcription, cell cycle control and dierentiation (Nevins, 1992; Philpott and Friend, 1994; Sherr, 1994) . Recently, Shin and coworkers (1995) have suggested that the accumulation of E2F-pRb2/p130 complexes is directly involved in the induction and in the maintainance of the dierentiative state of myogenic cells. From our results a more complex picture of E2F DNA binding activity during cell cycle and dierentiation of myogenic cells emerges. We found an oscillatory pattern of E2F changes from G 0 to S-phase in C2C12 cells similar to those present in 3T3 ®broblasts. In both cell types, during proliferation E2F4 associates with the G 1 /S speci®c cyclinA and its dependent kinase cdk2 in a complex that also contains p107. Since this complex is also aected by anti-pRb2/p130 antibodies, a separate complex containing E2F4, pRb2/130, its associated cyclin(s) and cdk(s) likely exists in C2C12 proliferating myoblasts. The E2F-G 1 /S complex disappears as the cells enter the G 0 /G 1 phase, whether C2C12 cells are in a con¯uent or a noncon¯uent state, and is replaced by a faster migrating complex. The major components of this latter complex are E2F4 and pRb2/p130. An E2F-p107 complex could be detected in the early phases of serum starvation-induced quiescence and gradually decreases along the dierentiation process (PLP, unpublished observations). The E2F-G 0 / G 1 complex persists after phenotypic and biochemical dierentiation into myotubes. In quiescent cells this complex disappears upon serum addiction, being replaced by the E2F-G 1 /S complex, coinciding with DNA synthesis. On the opposite, in myotubes serum fails to reinduce DNA synthesis and to aect the composition of this complex. Although a third faster migrating E2F complex, reported to contain pRb, can be detected in other cell lines (Shirodkar et al., 1992; Schwarz et al., 1993) , we were not able to supershift any E2F binding retarded band in extracts from myotubes in the ®rst days of dierentiation medium culture, with the panel of anti-pRb antibodies we used. Starting from the ®fth day of culture in dierentiation medium, extracts from myotubes can be supershifted by both anti-pRb and anti-pRB2/p130 antibodies (data not shown). These ®ndings ®t well with the E2F members expression levels. Indeed, according to the results described by Moberg et al. (1996) , we found that the speci®c p107-pRb2/p130 partner E2F4 is expressed in proliferating as well as arrested myoblasts and myotubes, and its levels do not change upon serum stimulation. In contrast, pRb speci®c partner E2F1, is present in proliferating muscle cells and its levels decrease in abundance in quiescent cells and in myotubes. Thus, in muscle cells E2F activity mainly results from the interactions between the p107 and pRb2/p130 pocket proteins and their partner(s). The limited contribution of E2F1 to E2F activity in these cells, would explain the failure to supershift the E2F complexes with antibodies against either E2F1 or its speci®c partner, pRb. However, pRb is easily detectable in E2F complexes from 5 old days myotubes in the absence of a clear supershift with anti-E2F1 antibodies. pRb up-regulation and his role during muscle dierentiation have been previously de®ned (Martelli et al., 1994; Schneider et al., 1994) . Our results support the notion that pRb can play a pivotal role in muscle dierentiation independently from its binding to E2F1. E2F free forms were detected in both cycling and quiescent C2C12 cells, although their abundance was clearly reduced in the latter. Dierently from Shin and coworkers (1995) , we found low levels of E2F free forms in dierentiated myotubes. The persistence of low levels of E2F free forms in G 0 arrested cells as well as in C2C12 myotubes has been shown by others (Dou et al., 1994; Halevy et al., 1995; Hertzinger et al., 1995; Wolf et al., 1995) . The presence of free E2F/DP activity is not directly involved in cell cycle progression because DNA synthesis is almost undetectable in quiescent cells. Free E2F/DP levels increase in response to serum and this correlates with induction of cell cycle progression into G 1 /S-phase. Interestingly, also in myotubes the slower migrating E2F/DP free band increases in response to serum, even in the absence of DNA synthesis. A possible explanation for this phenomenon relates to the presence of E2F sites required for transcriptional repression of genes, i.e. cdc2, E2F1, in G 0 and early G 1 (Lam and Watson, 1993; Adams and Kaelin, 1995) . An alternative explanation could be that E2F free forms might be involved in the activation of transcription of genes upregulated by growth factors stimulation of terminally dierentiated cells and linked to processes other than DNA synthesis (i.e. hypertrophy) (Endo et al., 1986; Puri et al., 1995) .
A critical dierence between quiescent C2C12 myoblasts and C2C12 myotubes resides in their ability to respond to growth factors stimulation with DNA synthesis (hyperplasia) and protein synthesis (hypertrophy) respectively (Puri et al., 1995) . It is conceivable that at least two separate steps, the G 0 arrest and the irreversible withdrawal from the cell cycle, should exist during myogenic dierentiation. Since the E2F-G 0 /G 1 complex appears as the cell enter G 0 phase, it might be directly involved in inducing cell cycle arrest. The ability of serum to abolish the E2F-G 0 /G 1 complex and to recruit the E2F-G 1 /S complex in quiescent myoblasts, but not in myotubes, favours the hypothesis that additional events play a key role in maintainance of this complex in dierentiated cells even upon serum stimulation, thereby keeping cells in permanent G 0 and shifting their response to growth factors from proliferative to hypertrophic. In agreement with previous studies reporting a critical role of MyoD/p21 in the induction of permanent cell cycle Figure 9 BrdU incorporation in C3H10T1/2 ®broblasts growing in 20% FCS containing medium, after microinjection with a MyoD encoding plasmid (pCMV-MyoD) or the control empty vector (pcDNA3). The ability of pCMV-MyoD to encode for MyoD in injected cells was preliminarly controlled by immunostaining using an anti-MyoD polyclonal antiserum. To easily identify productively injected cells, the pCMV-MyoD plasmid or the correspondent control vector, was coinjected together with a pCMV-CD20 expression vector, which encodes for the lymphocytes dierentiation membrane antigen CD20. After 36 h cells were ®xed and stained for CD20 expression (rhodamine) and BrdU incorporation (¯uorescein). BrdU was added 3 h before ®xation (Guo et al., 1995; Halevy et al., 1995) , we also provide evidence that, when MyoD DNA binding activity and p21 levels increase, C2C12 cells lose their ability to respond to serum with DNA synthesis and to maintain the E2F-G 0 /G 1 complex after serum stimulation. Since MyoD has been described to induce both cell cycle arrest and myogenic conversion in many cell types (Crescenzi et al., 1990; Sorrentino et al., 1990; Hollemberg et al., 1993) , we studied the behaviour of E2F complexes in nonmuscle cells ectopically expressing a hormone regulated ER-MyoD functional chimerae. In these cells, when MyoD is activated by estrogens, a temporally ordered sequence of events takes place: E-box binding, myogenin and p21 expression are induced, E2F4-pRb2/p130 complex become refractory to the addition of serum, re-entry in G 1 /S-phase in prevented and, ®nally, fusion into multinucleated myotubes can be observed. The E2F4-pRb2/p130 complex is unable to activate transcription from promoters containing E2F sites (Tommasi and Pfeier, 1995) . Indeed, we found a strong reduction of E2F driven reporter gene activity upon MyoD activity induction in C3H10T1/2 MyoD-ER cells. Taken together, these results support the hypothesis that E2F might be a downstream target of MyoD. It would have been interesting to assess whether MyoD, which is able to bind the E2F partners pRB and p107 (Gu et al., 1993) , might directly in¯uence the E2F activity by physical interaction with components of the multimeric E2F-G 0 /G 1 complex formed in response to serum withdrawal. The failure to detect any MyoD/E2F complexes interaction, would suggest that MyoD does not control E2F-complexes composition by physically interacting with E2F/DP proteins. The control of MyoD on E2F complexes composition and activity might be explained by the ability of MyoD to prevent the association of the predominant component of E2F complexes in muscle cells, E2F4, and its inhibitory partners, pRb2/p130 and p107, with G 1 cyclins/cdks, thus hampering the formation of the E2F complexes associated with the G 1 /S phase transition. It has been shown that a key mechanism through which MyoD induces cell cycle arrest, and thereby triggers myogenic dierentiation, involves the p53-independent induction of the cell cycle inhibitor p21 (Guo et al., 1995; Halevy et al., 1995) . p21 prevents the entry into S-phase by inhibiting G 1 cyclins/cdks activity (Sherr, 1994) . Cdks recruitment results in phosphorylation of pRb and Rbrelated proteins Mayol et al., 1995; Suzuki-Takahashi et al., 1995; Wolf et al., 1995; Claudio et al., 1996) . In C2C12 cells a direct correlation between phosphorylation of pRb and the ability to enter the cell cycle has been described (Gu et al., 1993) . Most of pRb is phosphorylated in cycling myoblasts, but rapidly becomes unphosphorylated when the cells are induced to dierentiate by growth factors removal. In myotubes pRb is refractory to rephosphorylation in response to mitogens (Gu et al., 1993) . Similarly, in L6 myoblasts induced to differentiate, both pRb2/p130 and p107 become underphosphorylated (Kiess et al., 1995) . Since we found the same E2F/G 0 /G 1 complex in C2C12 quiescent cells, before MyoD/p21 induction, and in C2C12 cells hyperexpressing the wild type as well as the mutant inactive form of p53 (PLP, unpublished observation), the association between E2F4 and pRb2/p130 is likely to be p53-and MyoD-independent. From our data it appears that the association between E2F4 and pRb2/ p130 re¯ects processes taking place prior to the irreversible cell cycle arrest and myogenic differentiation. Indeed, the E2F4-pRb2/p130 complex becomes unresponsive to serum only when MyoD activity increases and p21 upregulation is induced. As cells proliferate in response to serum stimulation, G 1 cyclins/ cdks are timely activated to phosphorylate key substrates such as pocket proteins and associate to E2F4-p107 and E2F4-pRb2/p130 in multimeric complexes found at the G 1 /S boundary. More recently, it has been described the ability of p21 to disrupt the interaction between cdk2 and the E2F-pRb2/p130 complex (Shiyanov et al., 1996) . Taken together, the available data suggest that MyoD induces the irreversible withdrawal from the cell cycle in muscle cells by upregulating p21 which, in turn, blocks G 1 cyclins/cdks activity. This would result in the accumulation of pRb and its related proteins in their unphosphorylated form and in the prevention of cyclins/cdks association with E2F4 and its inhibitory constraints (pRb2/p130 and p107). The ®nal outcome is the permanent arrest of cells in the G 0 phase that is reverted by those oncoviral proteins which aect MyoD function and/or directly dissociate and E2F/ Rb-related proteins interactions, but not by mitogens.
Materials and methods

Cell lines and culture conditions
C2C12 mouse cell line (Yae and Saxel, 1977) was obtained from G Cossu. Cells were grown in DMEM supplemented with 20% foetal bovine serum (cycling myoblasts) until they reached 80 ± 90% con¯uence, when dierentiation was induced by switching cell cultures to DMEM containing 2% foetal bovine serum (DM, dierentiation medium). Quiescent C2C12 myoblasts are noncon¯uent cells cultured in 0.1% foetal bovine serum for 48 h. They are negative for muscle speci®c markers (Myosin Heavy Chain and Desmin), and for BrdU, but still able to incorporate BrdU following serum stimulation (Puri et al., 1995) Stable lines in C3H10T1/2 were generated by cotransfecting 0.5 mg of the puromycin resistance gene vector pBABEpuro (kindly provided by H Land, ICRF, London, UK) together with 5 mg of MyoD-ER construct and 4.5 mg of mouse genomic DNA as a carrier, using the calcium phosphate precipitation method (Natoli et al., 1994) . The hybrid MyoD-ER construct, obtained from the fusion of the MyoD expressing vector EMC11S with the hormone-binding domain of the human estrogen receptor, was supplied by H Weintraub and previously characterized (Hollemberg et al., 1993) . Cells were kept in DMEM w : o phenol red and 20% double stripped de®ned supplemented calf serum in the presence of 2.5 mg/ml puromycin. After 1 week, resistant clones were picked and ampli®ed in duplicate. Clones that exhibited a morphological dierentiation after 48 to 72 h in the presence of estradiol (10 77 M) and 2% serum were further expanded.
Oligonucleotides
The wt E2F oligonucleotide probe sequences were derived from the adenovirus E2 promoter and consisted of one E2F site. The mutant E2F oligonucleotide contains a C-to-A mutation which determines a strongly reduced E2F binding activity. The E-box oligonucleotide probe sequence derived from the MCK enhancer was 5'-CCCCAA-CACCTGCTGCCTGA-3'.
DNA, transfections and CAT assay
ER-MyoD C3H10T1/2 cells were plated in medium containing 10% serum and transfected by the calcium phosphate method. After 24 h of incubation with the DNA precipitate, cells were washed and maintained for 72 h in medium containing 2% serum with or without 17-b Estradiol (Sigma), harvested and assayed for reporter gene expression as previously described (Natoli et al., 1994) . For these experiments we used a CAT reporter plasmid containing three E2F sites derived from the c-Myc P2 promoter (a gift from D Hall).
Northern blot
Total cellular RNA was extracted using the Chomczynski and Sacchi method (1987) . Ten micrograms of RNA from undierentiated MyoD-ER C3H10T1/2 cells or from cells harvested at dierent times after estradiol-induced differentiation were size-fractionated on 1.2 agarose ± 6.7% formaldehyde gels and transferred to nylon ®lters (Quiabrane, Quiagen), as described (Chomczynski and Sacchi, 1987) . RNA integrity and quantity was checked by ethidium bromide staining of ribosomal RNA. DNA fragments, puri®ed on agarose gel, were 32 P-labelled by random priming and used to probe the ®lters. The myogenin probe was EcoRI fragment from a pUC19 myogenin plasmid. The mouse p21 probe was obtained by C Schneider (Trieste, Italy 
Western blot
Total cell lysates were loaded and then resolved on SDS ± PAGE. After overnight electrophoresis, gels were equilibrated for 30 min in transfer buer (25 mM Tris, 200 mM Glycine) and transferred to PDVF membranes (Millipore) at 0.25 Ampere for 5 h at 48C. Membranes were ®rst incubated in 16 TBS (20 mM Tris, pH 6.5, 0.5 M NaCl) with 5% BSA for 1 h, then overnight with a speci®c antibodies ± anti-E2F1 (C20 from Santa Cruz), anti-E2F4 (C-108 from Santa Cruz) and anti-p21 antibody (C19 from Santa Cruz) at the dilution of 1 : 1000 in 0.56 TBS with 2.5% BSA and, ®nally, with a secondary antibody conjugated to horseradish peroxidase for 1 h. The antigen-antibody interaction was visualized by incubation for 30 s in a chemilluminant reagent (ECL Western blotting detection from Amersham) and exposure to an X-ray ®lm.
Electrophoretic mobility shift assay (EMSA) and antibody shift EMSA Electrophoretic mobility shift assays (EMSAs) for E2F were performed using 5 mg of whole cell extracts prepared as previously described (Pagano et al., 1992) , mixed with 2 ml of reaction buer (®nal concentration: NaCl 80 mM, HEPES 4 mM, MgCl 2 mM, glycerol 10%, DTT 0.5 mM, EDTA 0.2 mM), 1 ml of poly(dAdT) and a large excess of 32 P-end labelled double strand E2F oligonucleotide derived from the adenovirus E2 promoter. After 20 min at room temperature, samples were subjected to electrophoresis in 4% nondenaturing polyacrylamide gel, as described (Puri et al., 1995) . For competition studies a 100-to 200-fold molar excess of either unlabelled E2F wild type or E2F mutant oligonucleotide as well as of NFkB control oligonucleotide, were included in the reaction before speci®c labelled probe was added. DOC released E2F EMSAs were performed as described previously (Shirodkar et al., 1992) . For E-box EMSAs, cell extracts were prepared as previously described by Gu et al. (1993) . 20 mg of cell extract were combined in 30 ml of binding reaction containing 1 mg of poly(dIdC) in 20 mM HEPES (pH 7.6), 50 mM KCl, 1 mM dithioreitol, 1 mM EDTA, 5% glycerol and 32 P-end labelled E-box probe derived from the muscle creatine kinase promoter.
For antibody shift EMSAs antibodies were added to extracts at either room temperature or in ice for 30 min to 1 h (depending on the antibody or antiserum used) before the DNA binding reaction was started. Antibodies against E2F1 (C20 from Santa Cruz), E2F4 (C-108 from Santa Cruz), pRb (XZ133, G3-245, C36 from Pharmigen), p107 (SD9 from Pharmigen), pRb2/p130 (C-20 from Santa Cruz), cyclin A (BF683 from Pharmigen), cyclin B (from Oncogene Science), cdk2 (from UBI) and MyoD (a gift from M Crescenzi and S AlemaÁ ) were used.
Immunohistochemistry and DNA synthesis assay
For DNA synthesis assay BrdU (10 mM) was added to cells 3 h before cell ®xation. After washing, cells were ®xed in paraphormaldehyde 1% for 5 min at room temperature, rinsed in TBS (Tris Buer/NaCl 0.05 M pH 7.6), treated with TRITON-X 100 0.1% in TBS and incubated in 2 N HCl for 1 h at 378C. After neutralization in 0.1 M borate buer pH 8.5 cells were washed in TBS and processed for the immunohistochemical staining with anti-BrdU monoclonal antibody (Dako) according to the APAAP complexes method (Cordell et al., 1984) . Nuclei were counterstained with hematoxilin.
Immuno¯uorescence
Cells were washed in PBS, ®xed in a methanol/acetone 1 : 2 v/v solution, dried and incubated with either the anti-MHC polyclonal antiserum MF20 (a gift from G Cossu) or a polyclonal anti-p21 antibody (C19 from Santa Cruz) at 378C for 30 min. Speci®cally bound antibody was visualized by incubation with rhodaminated second-step antibody against immunoglobulin of the relevant species and observed by using a¯uorescent microscope. Immunouorescence for the detection of 5-bromo-2'-deoxy-uridine (BrdU), as indicator of DNA synthesis, was performed using the BrdU labelling and detection Kit (Boehringer). For double staining for MHC and BrdU, the anti-MHC antiserum MF-20 was used ®rst, before cells were incubated with the HCl containing buer and a separate immuno¯uorescence assay was performed.
Cells microinjection
For microinjection experiments, C2C12 cells were grown on small glass slides subdivided into numbered squares of 2 mm62 mm. Cells were microinjected with 100 molecules of DNA per nucleus, as previously described (Graessmann and Graessmann, 1983) . After injection cells were cultured in 20% FCS enriched medium for additional 36 h and then ®xed in a methanol/acetone solution 1 : 2 v/v, dried and subjected to immunostaining for the dierent proteins encoded by the expression plasmids and BrdU incorporation.
